Our novel pipeline of therapies for neurological and psychiatric disease is based on decades of research focused on cognitive neuroscience and the neurobiology of the aging brain.

Research at Johns Hopkins and leading research centers around the world have demonstrated that overactivity in key brain circuits contributes to cognitive impairment and drives neurodegeneration if not controlled.

This overactivity is a characteristic feature of mild cognitive impairment due to Alzheimer’s disease (MCI due to AD), the earliest symptomatic stage characterized by memory loss. Overactivity detected by brain imaging predicts the extent of neurodegeneration in the earliest stages of MCI due to AD and clinical progression to dementia.

Our most advanced clinical program targets MCI due to AD. We believe we have the potential to deliver the first and only therapeutic for hippocampal overactivity and potentially the first therapeutic to slow progression and delay the onset of Alzheimer’s dementia.


Our lead asset, currently in Phase 3 testing, is intended to treat MCI due to AD and delay progression to Alzheimer’s dementia.

Discovery: GABAA α5 positive allosteric modulators

Our novel late-stage discovery program offers therapeutic potential for a spectrum of untreated conditions including MCI due to AD, autism and schizophrenia.